The Medicines Company
https://www.themedicinescompany.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From The Medicines Company
Leqvio Sales Still Lag But Novartis Is Playing The Long Game
The twice-yearly cholesterol injectable approved in Europe 18 months ago is still not making any commercial headway but Novartis's CEO Vas Narasimhan has stressed that the groundwork for access to and education about Leqvio is being firmly laid.
FDA Asks Hyloris For More Data On Maxigesic IV
Hyloris has received a complete response letter from the US FDA asking for more information on its 505(b)(2) hybrid application for its Maxigesic IV intravenous analgesic for treating post-operative pain.
Finance Watch: Public Market Doldrums Have Not Sunk Private Company Funding Yet
ARCH closed a $3bn VC fund to end the month of June while in the same week six public biopharma firms said they are cutting jobs. Even so, some publicly traded companies have been able to launch sizeable offerings, including a $450m note sale by Cytokinetics and Xenon’s $250m follow-on.
ARCH Cites Stability Of Long-Term Investors In Raising $3bn Fund
ARCH Venture Partners brought in $2.975bn for its latest fund to give additional long-term investors a place at the table as the VC firm creates, builds and supports new early-stage biotechnology start-ups.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Annovation Biopharma, Inc.
- Boxford Subsidiary
- Curacyte Discovery GmbH
- Incline Therapeutics, Inc.
- ProFibrix B.V.
- Rempex Pharmaceuticals, Inc.
- Targanta Therapeutics Corporation
- Tenaxis Medical